CAJ | 학술논문

目的：观察FOLFOX4方案治疗晚期肝癌的疗效。方法：72例晚期肝癌患者，分为治疗组与对照组。治疗组采用FOLFOX4方案化疗，对照组采用最佳支持治疗。参照RECIST标准对该方案疗效进行评估，按照WHO抗癌药物毒副反应的分度标准评价毒副反应。结果：治疗组中40例晚期肝癌患者均可评价疗效，共完成化疗109个周期。肿瘤完全缓解（CR）0例，部分缓解（PR）8例，稳定（SD）19例，进展（PD）13例。CR＋PR率20．0％，总有效率67．5％。不良反应主要为胃肠道反应、骨髓抑制及外周神经毒性，对症治疗可缓解，均可以耐受。结论：FOLFOX4方案治疗晚期肝癌临床疗效满意，安全性高，毒副反应轻，值得临床推广应用。
목적：관찰FOLFOX4방안치료만기간암적료효。방법：72례만기간암환자，분위치료조여대조조。치료조채용FOLFOX4방안화료，대조조채용최가지지치료。삼조RECIST표준대해방안료효진행평고，안조WHO항암약물독부반응적분도표준평개독부반응。결과：치료조중40례만기간암환자균가평개료효，공완성화료109개주기。종류완전완해（CR）0례，부분완해（PR）8례，은정（SD）19례，진전（PD）13례。CR＋PR솔20．0％，총유효솔67．5％。불량반응주요위위장도반응、골수억제급외주신경독성，대증치료가완해，균가이내수。결론：FOLFOX4방안치료만기간암림상료효만의，안전성고，독부반응경，치득림상추엄응용。
Objective:To observe the efficiency of FOLFOX4 regimen in the patients with advanced hepatocellular carcinoma(HCC).Methods:All 72 patients with advanced HCC were divided into treatment group and the control group,treatment group were given systemic chemotherapy with FOLFOX4 regimen,the control group were given the best supportive treatment.The outcomes and the toxicity were evaluated by RECIST criterion and WHO standard for anticancer drugs toxicity.Results:All 40 patients of treatment group were successfully evaluated,completed 109 chemotherapy circles in total.None of the patients had a complete response to treatment,8 patients obtained partial re-sponse,19 patients stable disease,13 patients disease progression.The rate of CR+PR was 20.0%,the total effective rate was 67.5%.The side effects mainly were digestive tract reaction,bone marrow depression and neurotoxicity, which could be relieved after symptomatic treatment.Conclusion:FOLFOX4 is a safe and effective therapy regimen for patients with advanced HCC.